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Hepatitis B virus (HBV) infection is a major cause of mor-
bidity and mortality in human immunodeﬁciency virus
(HIV)–infected patients worldwide. It is unclear whether
HIV-related outcomes are affected by HBV coinfection. We
compared virological suppression and immunological recov-
ery during antiretroviral therapy (ART) of patients of differ-
ent HBV serological status in the Swiss HIV Cohort Study.
CD4 cell recovery during ART was signiﬁcantly impaired in
hepatitis B surface antigen–positive patients and in those
with anti-hepatitis B core antigen alone compared with
HBV-uninfected patients, despite similar virological efﬁcacy
of ART. CD4 increase in patients with resolved HBV infec-
tion was similar to that in HBV-uninfected individuals.
Keywords. hepatitis B infection; antiretroviral therapy out-
comes; immunological recovery; anti-hepatitis B core antigen alone.
Worldwide, hepatitis B virus (HBV) infection remains an
important cause of liver-related morbidity and mortality in
human immunodeﬁciency virus (HIV)-infected patients,
despite the availability of potent HBV drugs [1, 2]. HIV
infection accelerates the progression to liver ﬁbrosis in HBV-
infected patients and frequently leads to liver cirrhosis and he-
patocellular carcinoma [3, 4].
The impact of chronic HBV infection on antiretroviral
therapy (ART) outcomes in HIV-infected patients has been fre-
quently debated. Although virological response to ART seems
to be similar in HIV-monoinfected and HIV/HBV-coinfected
patients, the impact of HBV infection on immunological recov-
ery after the initiation of ART is controversial. Most studies
have been limited by a short duration of follow-up and by in-
clusion of a small number of HIV/HBV-coinfected patients.
Furthermore, no study has speciﬁcally compared immunologi-
cal recovery in hepatitis B surface antigen (HBsAg)–negative
patients exposed to HBV with those with chronic infection and
with those without previous exposure to HBV.
The Swiss HIV Cohort Study (SHCS; www.shcs.ch) is a pro-
spective cohort study with ongoing enrollment of HIV-positive
adults in Switzerland since 1988 [5]. In that study, all patients
are screened for HBV infection at baseline, and HIV viral loads
and CD4 cell counts are measured every 3 to 6 months thereaf-
ter. We compared HIV-related outcomes during the ﬁrst 3
years of ART between HIV-infected patients with or without
evidence of previous or current HBV infection.
METHODS
Local ethics committees of all participating study sites approved
the study, and written consent was obtained from all participants.
We included all patients who had a full serological assess-
ment of HBV infection before the initiation of ART or within
the ﬁrst month of ART and excluded those who did not have at
least a baseline and 1 follow-up CD4 count. Participants were
categorized into 4 main groups: (1) HBV-uninfected (HBsAg-
and anti-hepatitis B core antigen (HBc)–negative), (2) resolved
HBV infection (HBsAg-negative, anti-HBc–positive, and anti-
HBs–positive), (3) anti-HBc alone (HBsAg-negative, anti-HBc–
positive, andanti-HBs–negative), and (4)HBsAg-positive. Because
we intended to compare immunological recovery during the ﬁrst
3 years of ART across the different HBV status groups, patients
who experienced an HBsAg or anti-HBc seroconversion during
follow-up were excluded.
Baseline characteristics of the 4 HBV status groups were
compared using analysis of variance and χ² tests for continuous
and categorical variables, respectively. The 2 ART outcomes
evaluated were virological suppression (deﬁned as an HIV viral
load <50 copies/mL) during the ﬁrst year of treatment and CD4
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cell count recovery during 3 years of follow-up. Differences in
virological suppression between the 4 groups were evaluated
using multivariable Cox regression models. CD4 cell count re-
covery during the 3 ﬁrst years of ART for the 4 groups was
compared using multivariable linear mixed-effect regression
models. CD4 cell count response was square-root transformed,
and trajectories were modeled using fractional polynomials.
This model has been described in detail elsewhere [6]. Results
are presented as marginal CD4 trajectories. All multivariable
analyses were adjusted for sex, age category (16–29, 30–39, and
≥40 years), baseline CD4 cell count (<100, 100–199, and ≥200
cells/μL), HIV RNA category (≤4, 4–5, and ≥5 log copies/mL),
education level (none, basic, and high-level professional educa-
tion), HIV transmission group (men who have sex with men
[MSM], intravenous drug users [IDU], heterosexuals, or other),
region of origin (northwest/southern Europe, sub-Saharan
Africa, southeast Asia, or other), Centers for Disease Control
and Prevention stage, and hepatitis C virus (HCV) status (posi-
tive or negative anti-HCV antibodies). Multivariable models to
evaluate CD4 recovery were additionally adjusted for the use of
zidovudine (yes or no) as this drug has been shown in the
SHCS to impair immunological recovery [7].
The following sensitivity analyses were performed: CD4 count
increase was assessed in analyses restricted to patients who
achieved HIV virological suppression under ART, to white
MSM, to those treated with tenofovir (TNV), and stratiﬁed by
baseline CD4 cell count category (greater than or less than 200
cells/μL), initial ART regimen, and HCV status. To assess the
impact of ongoing HBV replication on immunological recovery,
we repeated our analyses in the subset of HBV-coinfected pa-
tients with successful ART who had an available HBV DNA
measurement after 1 year of ART (n = 159). Finally, we assessed
relative CD4 cell count (expressed as percentage of total lympho-
cyte count) increase during ART. All statistical analyses were per-
formed using Stata 12 (Stata Corp, College Station, TX).
RESULTS
Of 7671 patients who started ART, 4773 fulﬁlled the inclusion
criteria of a complete serological HBV assessment and at least 1
follow-up CD4 cell count measurement. Of these, 287 (6.0%)
were HBsAg positive, 633 (13.3%) anti-HBc alone, 1245 (26.1%)
had a resolved HBV infection, and 2608 (54.6%) were HBV un-
infected (Table 1). The proportion of patients from sub-Saharan
Table 1. Baseline Characteristics of Patients Starting Antiretroviral Therapy, by Hepatitis B Virus Status
Characteristic HBV-Uninfected
Resolved
HBV Infection
Anti-HBc
Alone HBsAg- Positive P Value
Number of patients (%) 2608 (54.6) 1245 (26.1) 633 (13.3) 287 (6.0)
Median age in years (IQR) 37 (31–44) 40 (33–47) 37 (32–43) 36 (31–42) <.001
Female gender (%) 744 (28.5) 344 (27.6) 214 (33.8) 76 (26.5) .03
Region of origin (%) <.001
Northwest/southern Europe 2079 (79.9) 883 (71.0) 429 (67.9) 182 (63.4)
Sub-Saharan Africa 230 (8.8) 217 (17.4) 142 (22.5) 63 (22.0)
Southeast Asia 82 (3.2) 59 (4.7) 16 (2.5) 18 (6.6)
Other 212 (8.1) 85 (6.8) 45 (7.1) 23 (8.0)
Risk group (%) <.001
Men who have sex with men 1053 (40.4) 549 (44.1) 139 (22.0) 109 (38.0)
Heterosexual 1263 (48.4) 424 (34.1) 248 (39.2) 106 (36.9)
Injecting drug users 178 (6.8) 218 (17.5) 226 (35.7) 58 (20.2)
Other 114 (4.4) 54 (4.3) 20 (3.2) 14 (4.9)
Professional education level (%) <.001
None 130 (5.1) 108 (9.0) 80 (13.3) 42 (15.0)
Basic 1650 (64.2) 790 (65.6) 415 (68.9) 169 (60.4)
High 790 (30.7) 307 (25.5) 107 (17.8) 69 (24.6)
Median CD4 count (IQR) 249 (134–364) 228 (113–340) 201 (107–302) 218 (92–322) <.001
Median log human immunodeficiency virus–RNA (IQR) 4.78 (4.11–5.30) 4.75 (4.05–5.27) 4.80 (4.02–5.34) 4.82 (4.08–5.33) .39
Centers for Diseases Control and Prevention stage (%) 387 (14.8) 240 (19.3) 124 (19.6) 46 (16.0) .001
Antiretroviral therapy regimen
Protease inhibitor–based (%) 1634 (62.7) 807 (64.8) 417 (65.9) 187 (65.2) .33
Zidovudine-containing (%) 1024 (39.3) 533 (42.8) 314 (49.6) 121 (42.2) <.001
Positive hepatitis C serology (%) 210 (8.1) 246 (19.8) 248 (39.2) 60 (20.9) <.001
Abbreviations: HBc, hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IQR, interquartile range.
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Africa was highest in the HBsAg-positive and anti-HBc alone
groups, whereas IDUs were overrepresented in the anti-HBc
alone group. Patients with anti-HBc alone had the lowest median
CD4 cell count at the start of ART, followed by HBsAg-positive
individuals. Baseline lymphocyte, leukocyte, and platelet counts
differed by <10% among HBV status groups.
During the ﬁrst year of ART, 2350 (90.1%) HBV-uninfected,
1083 (87.0%) with resolved HBV infection, 540 (85.3%) with anti-
HBc alone, and 245 (85.4%) HBsAg-positive patients achieved vi-
rological suppression (<50 copies/mL; see Supplementary Table 1).
In crude analyses, patients exposed to HBV infection were mar-
ginally less likely to experience virological suppression compared
with HBV-uninfected patients. After adjustment for all baseline
characteristics, there was no signiﬁcant difference in time to viro-
logical suppression between HBV-uninfected patients and those
in the other risk groups (resolved HBV infection: adjusted hazard
ratio [aHR], 0.93 and 95% conﬁdence interval [CI], .87–1.01;
anti-HBc alone: 1.02 and 0.92–1.13; and HBsAg-positive: 0.94
and 0.82–1.08; Supplementary Table 1).
Included patients had a median of 4.3 (interquartile range
[IQR], 3.5–5.1) CD4 cell count measurements performed per
year, with similar measurement frequencies across HBV status
groups. Estimated marginal CD4 cell count trajectories during
the ﬁrst 3 years of ART and by HBV status are shown in
Figure 1. During the ﬁrst 3 years of ART, HBV-uninfected pa-
tients and those with resolved HBV infection had signiﬁcantly
higher CD4 cell counts than patients in the other 2 groups (at 1
year: HBV-uninfected: 434 cells/μL and 95% CI, 427–440;
resolved HBV infection: 429 and 420–436; anti-HBc alone: 406
and 393–416; HBsAg-positive: 392 and 374–410; at 3 years:
HBV-uninfected: 504 and 496–511; resolved HBV infection:
496 and 485–506; anti-HBc alone: 461 and 446–475; HBsAg-
positive: 449 and 428–469). The differences in absolute CD4
cell counts between HBV-uninfected and resolved HBV infec-
tion, anti-HBc alone or HBsAg positive patients were −8 cells/
μL (95% CI, −21; 5), −43 (−60; −26), and −55 (−77; −33) after
3 years, respectively (see Supplementary Figure 1).
Differences in CD4 cell counts during the ﬁrst 3 years of
ART were consistent across sensitivity analyses (see Supple-
mentary Figure 1). There was a trend for an impaired immune
recovery in HBV-coinfected patients with a detectable HBV
viral load after 1 year compared with those who were HBV sup-
pressed (difference in CD4 counts at 1 year: −28 cells/μL [95%
CI, −76; 20] and at 3 years: −45 [95% CI, −100; 9]; P = .25 and
P = .10, respectively). Finally, HBV-uninfected patients and
those with resolved HBV infection had higher relative CD4 cell
counts compared with those of the other 2 groups, although
differences were small (differences in CD4 percentage between
HBV uninfected and resolved HBV infection, anti-HBc alone
or HBsAg positive patients were 2% (95% CI, 1; 2), 3% (2; 4),
and 3% (1; 4) after 3 years, respectively, P < .001).
DISCUSSION
In this nationwide representative, prospective cohort of HIV-
infected patients, coinfection with HBV adversely affected base-
line CD4 cell counts and immunological recovery during the
ﬁrst 3 years of ART. The impaired CD4 recovery was observed
in HBsAg-positive patients as well as in those with anti-HBc
alone. In contrast, virological response to ART was indepen-
dent of HBV infection.
The impact of HBV coinfection on immunological response
to ART has been a matter of debate. Although most studies, in-
cluding a large study from the EuroSIDA Group, did not show
any association between HBV coinfection and immunological
recovery during ART [8, 9], a few studies, mainly from middle-
and low-income countries, described an impaired CD4 re-
sponse in HBV-coinfected subjects, at least during the ﬁrst
months of ART [10, 11]. Our study suggests that coinfection
with HBV impairs CD4 recovery if immune responses fail to
maintain detectable levels of anti-HBs antibodies. The differ-
ences in immunological recovery between the HBV groups
were consistent across analyses in speciﬁc subpopulations, in-
cluding HIV-suppressed patients, those treated with TNV, and
MSM of white origin and in different baseline CD4 groups and
treatment regimens. In addition, all analyses were adjusted for a
wide range of confounders known to have an impact on CD4
recovery. In line with previous reports, time to HIV viral
load suppression was independent of HBV status [8, 9]. The
results from the sensitivity analyses and the similar virological
Figure 1. Immunological recovery during the ﬁrst 3 years of antiretrovi-
ral therapy, by hepatitis B virus status. All analyses are adjusted for sex,
age, region of origin, education level, transmission group, use of zidovu-
dine, baseline CD4 count, log viral load, Centers for Disease Control and
Prevention stage, and hepatitis C virus status.
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responses to ART strongly suggest that HBV coinfection is not
only a marker for patients with unfavorable predictors of CD4
recovery but also directly impairs immunological recovery
during ART. This is underlined by a trend for an impaired
immune recovery in HBV-coinfected patients with a detectable
HBV viral load after 1 year of ART compared with those with
suppressed DNA levels.
Several mechanisms might contribute to impaired T-cell re-
covery in HBsAg-positive patients. First, HBV viral replication
might adversely affect immune recovery. Apoptotic pathways
are upregulated in chronic HBV infection [12] and could con-
tribute to lower CD4 counts in untreated and treated HIV/
HBV coinfection. Second, it is conceivable that chronic HBV
infection contributes to some degree of systemic immune acti-
vation, which increases T-cell apoptosis [13]. Third, HBV-
related liver ﬁbrosis, which might increase splenic sequestration
of lymphocytes, could contribute to impaired T-cell recovery.
However, it is unlikely that splenic sequestration is the primary
mechanism leading to impaired T-cell recovery during ART for
the following reasons: impaired T-cell recovery was also observed
in those with anti-HBc alone where signiﬁcant liver ﬁbrosis is
very rare; total leukocyte, lymphocyte, and thrombocyte counts
were similar at baseline; and relative CD4 T-cell count recovery
was also signiﬁcantly impaired. In our study, impaired immune
recovery was also observed in patients treated with ART regi-
mens that included TNV, which is highly effective in suppressing
HBV replication [14]. However, even highly potent HBV drugs
are not able to fully suppress HBV viremia during the ﬁrst
months of treatment, which could explain impaired CD4 recov-
ery even in patients with optimal HBV treatment.
Interestingly, CD4 recovery was also impaired in the anti-HBc
alone group. Previous reports have demonstrated that anti-HBc
alone is associated with intermittent, mostly low-level HBV repli-
cation [15]. It is therefore possible that even low-level HBV repli-
cation and associated alterations of cytokine levels and/or
regulatory pathways impair CD4 recovery. The observation that
patients with anti-HBc alone are characterized by both failure to
maintain sufﬁcient levels of anti-HBs antibodies, and by im-
paired CD4 T-cell recovery suggests that several arms of the
immune responses are impaired in these individuals. To our
knowledge, this is the ﬁrst study to report a clear association
between the anti-HBc alone constellation and impaired CD4 cell
recovery. This ﬁnding highlights the similarities, from an immu-
nological standpoint, between HIV-infected patients with
chronic HBV infection and those with previous exposure to
HBV infection without detectable humoral immunity to HBV.
Our study did have limitations. Only a subset of HBsAg-
positive patients had an HBV DNA measurement available
after the ﬁrst year of ART. Furthermore, HBV DNA levels were
not available in most patients with anti-HBc alone, and there-
fore we could not assess the role of HBV replication in these
individuals.
Taken together, our study suggests a negative impact of HBV
coinfection on baseline immunological status before the start of
ART and on CD4 cell recovery during the ﬁrst 3 years of ART.
This impairment in immunological recovery is sustained and
consistent across different subpopulations, including patients
who have an adequate virological response to ART. The differ-
ences in CD4 recovery among the HBV status groups after the
ﬁrst year of ART are not recompensated after 3 years of ART.
This strengthens current recommendations to start ART early
in HBV-coinfected patients. More research on the direct
impact of HBV on cellular immunity is needed to understand
why coinfection with HBV impairs immune recovery during
ART and to determine whether intensiﬁed HBV treatment
could reverse this effect.
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